dizzy after semaglutide injection Vertigo from GLP-1 Injections Ozempic for Weight Loss (Semaglutide)

What are the potential long-term effects of blood clot-related injuries from Wegovy

How Mochi Health Compares to the Standard of Care The American Association of Clinical Endocrinology (AACE) 2023 obesity management algorithm recommends that patients with BMI 30 (or BMI 27 with at least one obesity-related comorbidity) be offered pharmacotherapy alongside lifestyle intervention, with prescriber follow-up at 4, 8, and 12 weeks after initiation, then every 3 months [13]

It is a prescription medicine with a defined role in diabetes and obesity care, it can help with glycaemic control and weight reduction, but it can also cause nausea, vomiting, constipation and other gastrointestinal side effects

10.1530/JOE-23-0342 J Endocrinol